Catégorie : Ressources Documentaires

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression, Leor Roseman, David J. Nutt, Robin L. Carhart-Harris, 2018

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Leor Roseman, David J. Nutt, Robin L. Carhart-Harris Psychedelic Research Group, Department of Medicine, Imperial College London, London, United Kingdom Frontiers in Pharmacology, 2018, 8, article 974. Doi : 10.3389/fphar.2017.00974 .   Introduction : It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) [...]

Lire la suite

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy, Tara C. Malone et al., 2018

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss, Samantha K. Podrebarac, Lindsey T. Owens, Anthony P. Bossis, Alexander B. Belser, Gabrielle Agin-Liebes, Michael P. Bogenschutz and Stephen Ross Frontiers in Pharmacology, 2018, 9, 256 doi: 10.3389/fphar.2018.00256   Abstract : A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A double-blind controlled trial was performed, where 29 [...]

Lire la suite

Clinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder, Michael P. Bogenschutz et al., 2018

Clinical Interpretations of Patients Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder BOGENSCHUTZ M.P., PODREBARAC S.K., DUANE J.H., AMEGADZIE S.S., MALONE T.C., ROSS L.T., MENNENGA S.E. Frontiers in Pharmacology, 2018, 9, article 100. Doi : 10.3389/fphar.2018.00100   Abstract : After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process [...]

Lire la suite

Cannabis and anxiety : a critical review of the evidence, José Alexandre Crippa et al., 2009

Cannabis and anxiety: a critical review of the evidence José Alexandre Crippa, Antonio Waldo Zuardi, Rocio Martin-Santos, Sagnik Bhattacharyya, Zerrin Atakan, Philip McGuire and Paolo Fusar-Poli Human Psychopharmacology Clinical and Experimental, 2009, 24, 515-523.   Background : Anxiety reactions and panic attacks are the acute symptoms most frequently associated with cannabis use. Understanding the relationship between cannabis and anxiety may clarify the mechanism of action of cannabis and the pathophysiology of anxiety. Aims of the present study were to review the nature of the relationship between cannabis use and anxiety, as well as the possible clinical, diagnostic and causal implications. Method : Systematic review of the [...]

Lire la suite

Age-related differences in the impact of cannabis use on the brain and cognition : a systematic review, Claire Gorey et al., 2019,

Age-related differences in the impact of cannabis use on the brain and cognition : a systematic review Claire Gorey, · Lauren Kuhns, · Eleni Smaragdi, · Emese Kroon, · Janna Cousijn European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00981-7   Abstract The impact of cannabis on the adolescent compared to adult brain is of interest to researchers and society alike. From a theoretical perspective, adolescence represents a period of both risk and resilience to the harms of cannabis use and cannabis use disorders. The aim of this systematic review is to provide a critical examination of the moderating role of age on the relationship between [...]

Lire la suite

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast, 2017

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Progress in Neuropsychopharmacology & Biological Psychiatry, 2017. http://dx.doi.org/10.1016/j.pnpbp.2017.08.022   A B S T R A C T Methamphetamine (METH) is a widely abused and a severely addictive psychostimulant. Relapse is the main cause of concern when treating addiction. It could manifest after a long period of abstinence. Previous studies showed that there is a strong connection between sleep impairment and relapse. Also, it has been reported that cannabidiol might be a potential treatment for drug craving and relapse. [...]

Lire la suite

Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats, Gracie L. Hay et al., 2018

Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats Gracie L. Hay, Sarah J. Baracz, Nicholas A. Everett, Jessica Roberts, Priscila A. Costa, Jonathon C. Arnold, Iain S. McGregor and Jennifer L. Cornish Journal of Psychopharmacology, 2018, 32, (12), 1369-1378. DOI : 10.1177/0269881118799954 ,  journals.sagepub.com/home/jop   Abstract Background : Methamphetamine is an addictive stimulant that can cause many adverse physical, psychological and psychosocial effects. Preliminary evidence shows cannabidiol, a non-intoxicating constituent of the cannabis plant, may have efficacy in treating opioid and nicotine dependence. However, no study has yet examined whether cannabidiol treatment might impact on methamphetamine addiction. Aims : The current study [...]

Lire la suite

REVIEW : Cannabidiol – Recent Advances, Raphael Mechoulam, 2007

REVIEW : Cannabidiol – Recent Advances Raphael Mechoulam, Maximilian Petersa, Eric Murillo-Rodriguez and Lumïr O. Hanus Chemistry and Biodiversity, 2007, 4, 1678-1692.   The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity. Contents 1. Introduction 2. Mechanisms of Cannabidiol Action 2.1. Cannabidiol: an [...]

Lire la suite

Les Phyto-cannabinoïdes Non-psychotropes : Les nouvelles Opportunités d’une plante ancienne, Angelo A. Izzo, Raphael Mechoulam et al., 2009

Les Phyto-cannabinoïdes Non-psychotropes* : Les nouvelles Opportunités d'une plante ancienne.(*NdT : non-stupéfiants) Angelo A. Izzo, Francesca Borrelli, Raffaele Capasso, Vincenzo Di Marzo and Raphael Mechoulam Trends in Pharmacological Sciences - CELL Press, 2009, 30, 10, 515-27. doi: 10.1016/j.tips.2009.07.006.   Le Δ9-tetrahydrocannabinol (Δ9THC) se lie aux récepteurs endocannabinoïdes (CB1 et CB2) qui sont activés par les cannabinoïdes endogènes (endocannabinoïdes) et qui sont impliqués dans une large gamme de processus physiopathologiques (exemple: modulation de la libération de neurotransmetteurs, régulation de la perception de la douleur, régulation des fonctions cardiovasculaires, gastro-intestinales et hépatiques). Les effets psychotropes bien connus du Δ9THC qui sont véhiculés par l'activation des récepteurs CB1 [...]

Lire la suite

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, Orrin Devinsky et al., 2018

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome Orrin Devinsky,  Anup D. Patel, Elizabeth A. Thiele, Matthew H. Wong,  Richard Appleton, Cynthia L. Harden, Sam Greenwood,  Gilmour Morrison, and Kenneth Sommerville,  On behalf of the GWPCARE1 Part A Study Group Neurology® 2018, 0:e1-e8.   doi:10.1212/WNL.0000000000005254 Abstract Objective : To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods : Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers [...]

Lire la suite